ADMA Biologics, Inc. (ADMA) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 2.31B USD. 52-week range 7.21 to 20.46 USD. Trailing P/E 14.8. Data as of 2026-10-09.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the ...